Abstract:Purinergic receptors are well-established modulators of inflammatory processes, primarily through detection of extracellular nucleotides that are released by dying or infected cells. Emerging literature has demonstrated that inhibition of these inflammatory receptors can block HIV-1 productive infection and HIV-1-associated inflammation. The specificity of receptor type and mechanism of interaction has not yet been determined. Here, we characterize the inhibitory activity of P2X1 receptor antagonists, NF279 and NF449, in cell lines, primary cells, and a variety of HIV-1 envelope (Env) clades. NF279 and NF449 blocked productive infection at the level of viral membrane fusion, with a range of inhibitory activities against different HIV-1 Env isolates. A mutant virus carrying a truncation deletion of the C-terminal tail of HIV-1 Env glycoprotein 41 (gp41) showed reduced sensitivity to P2X1 antagonists, indicating that the sensitivity of inhibition by these molecules may be modulated by Env conformation. In contrast, a P2X7 antagonist, A438079, had a limited effect on productive infection and fusion. NF279 and NF449 interfered with the ability of the gp120 variable regions 1 and 2 (V1V2)-targeted broadly neutralizing antibody PG9 to block productive infection, suggesting that these drugs may antagonize HIV-1 Env at gp120 V1V2 to block viral membrane fusion. Our observations indicate that P2X1 antagonism can inhibit HIV-1 replication at the level of viral membrane fusion through interaction with Env. Future studies will probe the nature of these compounds in inhibiting HIV-1 fusion and the development of small molecules to block HIV-1 entry via this mechanism.IMPORTANCE While effective treatment can lower the severe morbidity and mortality associated with HIV-1 infection, patients infected with HIV-1 suffer from significantly higher rates of noncommunicable comorbidities associated with chronic inflammation. Emerging literature suggests a key role for P2X1 receptors in mediating this chronic inflammation, but the mechanism is still unknown. Here, we demonstrate that HIV-1 infection is reduced by P2X1 receptor antagonism. This inhibition is mediated by interference with HIV-1 Env and can impact a variety of viral clades. These observations highlight the importance of P2X1 antagonists as potential novel therapeutics that could serve to block a variety of different viral clades with additional benefits for their anti-inflammatory properties.

Urokinase (uk) inhibits infecttvity by common north american strains of hiv-1

Urokinase Inhibits Infectivity by HIV- 1 in vitro

USP49 Potently Stabilizes APOBEC3G Protein by Removing Ubiquitin and Inhibits HIV-1 Replication

Urokinase plasminogen activator surface receptor restricts HIV-1 replication by blocking virion release from the cell membrane

Safety evaluation of the rhpro-urokinase

Inactivation of the Intrinsic Activity of Pro-urokinase by Diisopropyl Fluorophosphate is Reversible

Catalytic and Fibrinolytic Properties of Recombinant Urokinase Plasminogen Activator from E. Coli, Mammalian, and Yeast Cells.

Correction: HIV-1 Fusion is Blocked Through Binding of GB Virus C E2D Peptides to the HIV-1 Gp41 Disulfide Loop.

Short Communication: in VitroSynergy Between Peptides or Neutralizing Antibodies Targeting the N- and C-Terminal Heptad Repeats of HIV Type 1 Gp41

A heterocyclic compound inhibits viral release by inducing cell surface BST2/Tetherin/CD317/HM1.24

Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.

P2X1 Selective Antagonists Block HIV-1 Infection through Inhibition of Envelope Conformation-Dependent Fusion

Current Status of the Pharmacokinetics and Pharmacodynamics of HIV-1 Entry Inhibitors and HIV Therapy

A Transitional State of Pro-Urokinase That Has a Higher Catalytic Efficiency Against Glu-Plasminogen Than Urokinase.

The Kinetics of Plasminogen Activation by Thrombin-Cleaved Pro- Urokinase and Promotion of Its Activity by Fibrin Fragment E-2 and by Tissue Plasminogen Activator

ADS-J1, an Entry Inhibitor Targeting Gp41, Prevents HIV-1 Transmission in the in Vitro and Ex Vivo Models.

Analysis of the forces which stabilize the active conformation of urokinase-type plasminogen activator.

HIV-1 Gp41-Targeting Fusion Inhibitory Peptides Enhance the Gp120-Targeting Protein-Mediated Inactivation of HIV-1 Virions

Human immunodeficiency virus type 1 (HIV-1) inhibitory interactions between protease inhibitor Ro 31-8959 and zidovudine, 2',3'-dideoxycytidine, or recombinant interferon-alpha A against zidovudine-sensitive or -resistant HIV-1 in vitro

Prourokinase Mutant That Induces Highly Effective Clot Lysis Without Interfering With Hemostasis

Knocking-Out Concentrations of HIV-1-Specific Inhibitors Completely Suppress HIV-1 Infection and Prevent the Emergence of Drug-Resistant Virus